Supplementary Table 1. Checklist for reporting human islet preparations used in research

Islet preparation	1	2	3	4	5	6	7	8[a]
Unique identifier	SN7	SN8	SN9	SN10	SN11	SN12	SN13	SN14
Donor age, yr	57	69	63	60	44	19	62	62
Donor sex, male/female	F	M	F	F	F	F	M	M
Donor BMI, kg/m^2	23.1	27.8	23.0	22.0	27.0	22.9	32.7	26.7
Donor HbA1c or other measure of blood glucose control	5.5	5.8	5.9	5.4	5.4	5.5	6.2	6.1
Origin/source of islets[b]	Seoul National University Hospital							
Islet isolation centre	Seoul National University Hospital							
Donor history of diabetes? Yes/No	No	No	No	No	No	No	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration, yr								
Glucose-lowering therapy at time of death[c]								
Donor cause of death	Not applied. Living donors.							
Warm ischaemia time, hr	Not applied. Living donors.							
Cold ischaemia time, hr	Less than 1.5							
Pancreas weights, g	0.84	3.05	1.06	0.70	0.75	0.50	0.21	5.01
No. of islets isolated	260	260	600	600	800	700	300	600
Estimated purity, %	Nearly 100% because a skilled researcher hand-picked the islets using pipettes on microscope, following separation by ficoll gradients.							
Estimated viability, %	Not assayed							
Total culture time, hr[d]	45–60							
Glucose-stimulated insulin secretion or other functional measurement[e]	Fig. 2							
Handpicked to purity? Yes/No	Yes							
Additional notes: pancreatic diseases leading to partial pancreatectomy	SCT	SCT	MCT	NT	NT	SCT	NT	NT

Adapted from Hart et al. [21] with permission from Springer Nature.

BMI, body mass index; HbA1c, glycosylated hemoglobin; SCT, serous cystic tumor; MCT, mucinous cystic tumor; NT, neuroendocrine tumor.

[a]If you have used more than eight islet preparations, please complete additional forms as necessary, [b]For example, IIDP, ECIT, Alberta IsletCore, [c]Please specify the therapy/therapies, [d]Time of islet culture at the isolation centre, during shipment and at the receiving laboratory, [e]Please specify the test and the results.